Pfizer's Xeljanz Approval In UC Includes Postmarket Study On Long-Term Effects
JAK inhibitor, now first oral UC medication in US, is approved for both 5mg and 10mg, but label currently discourages 10mg after 16 weeks.
You may also be interested in...
Analyst speculates that risk of pulmonary embolism for a higher unapproved dose of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.
Albert Bourla will face opportunities and potential pitfalls.